Tag: Cancer: Leukemia
Leukemia, and Its Treatment, May Pose Neurocognitive Risks
Cerebrospinal fluid biomarkers may identify those at greater risk for poor neuro-related outcomes
Molecular Minimal Disease in Remission Predicts AML Relapse
Persistence of non-DTA mutations during remission linked to rates of relapse, survival
Treatment-Free Remission Feasible After Nilotinib in CML
For patients with chronic myeloid leukemia in chronic phase, TFR is feasible after second-line treatment
TP53 Variants Linked to Childhood ALL, Poor Outcomes
Carrying germline variants linked to decreased event-free, overall survival; higher risk of second cancers
Adipocytes Metabolize, Inactivate Daunorubicin
Adipocytes metabolize daunorubicin to daunorubicinol, reducing its anti-leukemia effect
Zelboraf Approved for Use in Erdheim-Chester Disease
Kinase inhibitor (vemurafenib) for use in patients with BRAF V600 mutation
Leukemia Patients Who Survive Severe GVHD Often Fare Worse
Those who develop severe acute graft-versus-host after stem cell transplant have higher mortality
Immune Status Tied to Outcomes in Third-Gen CAR T-Cell Therapy
In leukemia/lymphoma, after treatment CD19-targeting chimeric antigen receptor T-cell therapy
FDA Approves First Gene Therapy in the United States
Kymriah approved for patients up to 25 years of age with refractory or relapsed B-cell precursor ALL
FDA Approves New Treatment for Acute Lymphoblastic Leukemia
For patients with relapsed or refractory B-cell ALL who have received one or two prior treatments
